deepeye® Research is designed to empower retinal therapy study teams with actionable insights, leveraging advanced AI to analyze complex datasets. By building on the proven methodologies of one of the EU’s leading reading and study centers, involved in major phase III and IV anti-VEGF trials, we take retinal research to the next level.
With its advanced AI capabilities, deepeye® Research is designed to transform how retinal therapy studies are conducted, providing unmatched support across various phases of clinical research.
Optimize phase IV trials by uncovering unique therapy patterns and efficacy trends.
Enhance phase II-III research with retrospective dataset reviews, including quality assurance.
Standardize imaging data to ensure consistency and improve study reliability.
deepeye® Research is built on four core features that redefine how retinal therapy studies are conducted, delivering precision, efficiency, and groundbreaking insights.
Adaptable to diverse study needs, deepeye® Research supports phase IV studies, retrospective analyses for phase II-III trials, and quality assurance samples.
Integrates large, heterogeneous OCT imaging and clinical datasets, ensuring a robust foundation for analysis.
Produces anonymized, standardized, and enhanced imaging data, delivering AI-driven reports that provide unique insights into therapy patterns and potential improvements.
Generates high-value outputs, including detailed AI reports and optional publications, tailored to meet the needs of pharma, device manufacturers, and healthcare payors.
